Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.
Berdel AF, Ruhnke L, Angenendt L, Wermke M, Röllig C, Mikesch JH, Scheller A, Hemmerle T, Matasci M, Wethmar K, Kessler T, Gerwing M, Hescheler D, Schäfers M, Hartmann W, Altvater B, Rossig C, Bornhäuser M, Lenz G, Stelljes M, Rueter B, Neri D, Berdel WE, Schliemann C.
Berdel AF, et al. Among authors: schafers m.
Blood Adv. 2022 Jun 28;6(12):3684-3696. doi: 10.1182/bloodadvances.2021006909.
Blood Adv. 2022.
PMID: 35468621
Free PMC article.
Clinical Trial.